vaccin
one
effici
way
erad
infecti
diseas
human
anim
materi
tradit
use
vaccin
attenu
inactiv
pathogen
approach
sometim
limit
fact
materi
vaccin
effici
avail
gener
deleteri
side
effect
possibl
theoret
altern
use
recombin
protein
pathogen
impli
protein
capac
vaccin
identifi
produc
suffici
quantiti
low
cost
genet
modifi
organ
harbor
pathogen
gene
fulfil
condit
microorgan
anim
cell
well
transgen
plant
anim
sourc
recombin
vaccin
system
get
improv
advantag
limit
adjuv
must
gener
ad
recombin
protein
enhanc
vaccin
capac
impli
protein
use
vaccin
purifi
avoid
immun
contamin
effici
recombin
vaccin
poorli
predict
multipl
protein
variou
mode
administr
must
therefor
empir
evalu
casebycas
basi
structur
recombin
protein
composit
adjuv
mode
administr
vaccin
strong
fulli
predict
impact
immun
respons
well
protect
level
pathogen
recombin
protein
theoret
also
use
carrier
epitop
pathogen
increas
knowledg
pathogen
genom
avail
effici
system
prepar
larg
amount
recombin
protein
greatli
facilit
potenti
use
recombin
protein
vaccin
present
review
critic
analysi
state
art
field
pioneer
work
e
jenner
l
pasteur
other
made
possibl
erad
smallpox
earth
vaccin
larg
number
peopl
diseas
like
hepat
b
gastroenter
induc
rotaviru
might
also
markedli
reduc
use
vaccin
method
commonli
use
prepar
vaccin
consist
obtain
suffici
amount
attenu
inactiv
pathogen
administ
materi
human
anim
attenu
form
pathogen
gener
obtain
natur
mutat
follow
select
number
random
mutant
may
increas
use
mutagen
chemic
biotechnolog
annual
review
volum
issn
doi
r
elsevi
bv
right
reserv
irradi
altern
known
virul
gene
may
remov
pathogen
genom
use
genet
engin
nativ
pathogen
may
also
inactiv
physicochem
treatment
approach
suffer
sever
limit
attenu
exploit
form
pathogen
may
obtain
case
tool
commonli
use
purpos
anim
cell
line
chicken
egg
live
vaccin
obtain
way
gener
potent
composit
complex
may
induc
sever
deleteri
effect
preclud
use
case
liveattenu
vaccin
rotaviru
induc
sever
intestin
inflamm
intussuscept
new
vaccin
still
contain
attenu
retroviru
develop
expect
reduc
side
effect
even
case
success
possibl
unknown
side
effect
may
persist
live
vaccin
one
vaccin
person
effect
protect
still
shed
wild
activ
virus
contribut
support
epidem
anoth
problem
gener
use
attenu
inactiv
pathogen
difficult
make
distinct
anim
human
vaccin
infect
inde
antibodi
pathogen
present
blood
categori
anim
peopl
absenc
one
gene
pathogen
may
make
distinct
possibl
vaccin
infect
individu
altern
serum
antibodi
marker
result
immun
foreign
antigen
ad
vaccin
may
also
distinguish
vaccin
infect
individu
viral
vector
use
express
gene
code
vaccin
protein
anoth
pathogen
system
cumul
advantag
use
effici
viral
vector
transfer
express
foreign
gene
sever
strain
vaccinia
viru
adenovirus
differ
origin
use
success
vaccin
anim
nake
dna
form
plasmid
harbor
gene
code
vaccin
protein
also
simpl
versatil
safe
tool
vaccin
anim
method
still
need
improv
approv
anim
human
possibl
altern
consist
use
subunit
pathogen
contain
one
protein
organ
pathogen
form
viruslik
particl
vlp
case
virus
approach
expect
safe
materi
contain
nucleic
acid
pathogen
vector
use
carri
gene
code
vaccin
protein
may
plasmid
viral
vector
approach
also
make
possibl
distinct
vaccin
infect
individu
antibodi
rais
pathogen
protein
infect
vaccin
prepar
recombin
vaccin
may
effici
easi
implement
inde
long
studi
may
necessari
defin
protein
suffici
vaccin
capac
ideal
effici
form
pathogen
protein
gener
obtain
pathogen
suffici
quantiti
system
capabl
provid
larg
amount
recombin
protein
low
cost
must
implement
isol
protein
also
gener
less
potent
induc
immun
respons
whole
pathogen
mainli
live
impli
use
potent
adjuv
must
devoid
deleteri
side
effect
vaccin
protein
must
therefor
purifi
prevent
immun
respons
contamin
vaccin
potenc
recombin
protein
larg
unpredict
oblig
experiment
evalu
effici
variou
mode
administr
differ
adjuv
increas
knowledg
pathogen
genom
offer
multipl
possibl
identifi
protein
even
epitop
capabl
induc
protect
pathogen
becom
possibl
test
one
one
differ
antigen
pathogen
approach
impli
systemat
clone
gene
code
put
vaccin
protein
prepar
correspond
protein
evalu
capac
use
vaccin
bruteforc
method
alreadi
result
unpreced
burst
new
antigen
discoveri
less
labori
approach
recent
met
great
success
identifi
new
antigen
group
streptococcu
method
consist
releas
fragment
surfac
antigen
treat
bacteria
proteas
peptid
identifi
mass
spectrometri
correspond
gene
clone
prepar
evalu
correspond
antigen
method
allow
fast
identif
antigen
vaccin
method
appli
number
pathogen
sever
system
becom
effici
produc
larg
amount
recombin
protein
includ
vaccin
among
system
transgen
anim
plant
pathogen
protein
potent
vaccin
properti
may
theoret
use
carrier
epitop
pathogen
practic
gener
fusion
protein
harbor
epitop
capabl
induc
protect
pathogen
easi
task
present
review
examin
differ
step
prepar
evalu
recombin
protein
use
vaccin
differ
system
produc
recombin
vaccin
differ
system
implement
produc
recombin
protein
experiment
use
biotechnolog
applic
includ
peptid
chemic
synthesi
microorgan
anim
cell
plant
cell
transgen
plant
transgen
anim
tabl
number
peptid
cover
pathogen
protein
known
induc
vaccin
may
chemic
synthes
test
capac
induc
protect
pathogen
achiev
fragment
protein
rotaviru
essenti
epitop
protein
vaccin
may
thu
determin
also
make
possibl
identif
mechan
immun
respons
induc
epitop
peptid
contain
relev
epitop
may
chemic
synthes
chemic
link
carrier
protein
result
materi
may
use
vaccin
altern
fusion
recombin
protein
contain
epitop
interest
carrier
protein
known
induc
vaccin
may
prepar
see
microorgan
first
use
produc
recombin
protein
human
insulin
prepar
last
twenti
year
bacteria
although
highli
effici
protein
bacteria
show
limit
possibl
due
fact
fold
properli
number
protein
proceed
posttransl
modif
bacteria
may
produc
high
amount
recombin
protein
form
inclus
bodi
preclud
easi
purif
protein
toxic
bacteria
prepar
way
interestingli
protein
prepar
bacteria
prove
vaccin
capac
almost
similar
protein
prepar
insect
cell
infect
recombin
baculoviru
harbor
correspond
viral
gene
yeast
may
easili
transform
often
produc
limit
amount
recombin
protein
glycosyl
unduli
glycosyl
interestingli
sever
gene
code
glycosyl
enzym
transfer
yeast
becom
capabl
ad
sever
carbohydr
present
human
protein
interest
mention
part
hepat
b
vaccin
prepar
recombin
yeast
also
import
note
viral
protein
prepar
yeast
form
correctli
polym
disulfid
bridg
protein
must
therefor
chemic
reduc
allow
appropri
format
disulfid
crosslink
vlp
full
vaccin
potenc
variou
anim
cell
current
use
prepar
recombin
protein
experiment
studi
biotechn
applic
interest
note
recombin
protein
use
pharmaceut
prepar
anim
cell
one
cell
system
frequent
use
laboratori
prepar
viral
protein
cell
system
system
rel
simpl
use
prove
effici
prepar
wellassembl
viral
protein
form
vlp
reach
goal
viral
gene
introduc
baculoviru
homolog
recombin
insect
cell
result
viral
particl
use
infect
larg
number
cell
produc
high
amount
viral
protein
secret
store
cytoplasm
form
spontan
wellshap
vlp
vlp
isol
cell
lysat
purifi
use
differ
protocol
one
consist
fraction
vlp
cesium
chlorid
gradient
sever
vlp
prepar
way
show
structur
similar
nativ
correspond
viral
complex
judg
electron
microscopi
biochem
analysi
baculoviru
system
make
possibl
prepar
vlp
broad
varieti
virus
simpl
doubl
capsid
envelop
tool
allow
prepar
vlp
suffici
quantiti
determin
structur
evalu
vaccin
properti
system
easili
scale
prepar
vaccin
industri
scale
mammalian
cell
use
prepar
recombin
protein
cho
chines
hamster
ovari
cell
frequent
use
prepar
pharmaceut
protein
one
advantag
cell
proceed
posttransl
modif
protein
howev
glycosyl
recombin
protein
secret
cho
may
incomplet
due
satur
glycosyl
enzym
extrem
carbohydr
moieti
secret
protein
contain
quantit
termin
sialic
acid
addit
gene
code
glycosyl
enzym
improv
qualiti
secret
protein
moreov
human
cell
synthes
sialic
acid
nana
nacetylneuramin
acid
form
rabbit
chicken
cell
wherea
rumin
cell
synthes
also
nglycosylneuramin
acid
glycosyl
protein
essenti
activ
protein
nonglycosyl
protein
short
halflif
vivo
unexpectedli
peptid
candid
becom
vaccin
malaria
loos
capac
vaccin
mice
glycosyl
form
exemplifi
necess
control
glycosyl
recombin
vaccin
case
one
case
prepar
vaccin
hepat
b
anim
cell
use
provid
vaccin
essenti
similar
obtain
yeast
although
effici
cho
cell
remain
costli
poorli
flexibl
system
prepar
recombin
protein
inde
l
fermentor
cost
million
dollar
five
year
need
build
tool
first
transgen
plant
obtain
apart
use
basic
studi
transgen
plant
increasingli
use
improv
food
product
idea
use
transgen
plant
sourc
recombin
protein
becom
realiti
number
enzym
use
research
diagnosi
current
produc
industri
scale
produc
pharmaceut
plant
ambiti
project
system
offer
sever
advantag
also
seriou
limit
variou
plant
speci
obtain
transgen
two
essenti
method
implement
transfer
gene
plant
one
tool
agrobacterium
tumefacien
system
contain
natur
vector
abl
transfer
foreign
gene
plant
genom
known
biolist
consist
project
minut
bullet
cover
dna
plant
cell
case
viabl
plant
develop
transform
somat
cell
larg
number
transgen
plant
obtain
make
possibl
select
transgen
intact
function
foreign
protein
may
store
leav
seed
accord
promot
use
leav
abund
may
difficult
purifi
protein
interest
due
presenc
proteas
substanc
like
polyphenol
welltoler
patient
amount
recombin
protein
prepar
plant
virtual
unlimit
product
cost
low
moreov
agricultur
techniqu
offer
great
flexibl
scale
leav
seed
contain
protein
interest
store
easili
also
simpl
rescu
plant
line
establish
master
bank
allow
reproduc
product
protein
plant
cell
abl
fold
protein
associ
subunit
form
antibodi
essenti
effici
anim
cell
contrari
plant
cell
add
carbohydr
protein
chain
anim
cell
protein
synthes
plant
cell
termin
sialic
acid
contain
xylos
may
induc
deleteri
immun
respons
experi
progress
modifi
protein
glycosyl
transfer
variou
gene
respons
addit
sugar
protein
way
similar
mammalian
cell
protein
prepar
plant
littl
chanc
contain
pathogen
human
anim
use
transgen
plant
prepar
recombin
protein
rais
littl
ethic
problem
one
major
concern
uncontrol
dissemin
protein
thu
antigen
plant
cultur
open
field
low
amount
antigen
might
induc
toler
human
basal
unknown
vaccin
problem
solv
easili
plant
may
steril
prevent
dissemin
transgen
anoth
proposit
retain
compani
involv
product
recombin
protein
plant
limit
gene
transfer
plant
use
human
feed
tobacco
alfalfa
stop
complet
uncontrol
diffus
antigen
one
possibl
suppress
problem
consist
keep
plant
greenhous
technic
possibl
would
enhanc
markedli
product
cost
reduc
attract
plant
purpos
satisfactori
approach
could
use
plant
cultur
easili
larg
quantiti
low
cost
confin
area
encourag
experi
shown
duckwe
microalga
could
provid
human
larg
amount
protein
produc
perfectli
wellcontrol
condit
anoth
possibl
would
use
cultur
plant
cell
recent
studi
suggest
perspect
offer
attract
altern
case
sever
antigen
potenti
use
vaccin
produc
transgen
plant
capsid
protein
rotaviru
found
tuber
leav
transgen
potato
amount
solubl
tuber
protein
first
case
tuber
leav
second
case
oral
immun
tuber
tissu
gener
measur
titer
igg
serum
iga
intestin
proof
concept
insuffici
conclud
method
may
contribut
vaccin
fragment
protein
sar
viru
sever
acut
respiratori
syndrom
found
transgen
tomato
nicotinefre
tobacco
oral
administr
transgen
tomato
mice
induc
synthesi
iga
antibodi
suggest
mucos
immun
respons
trigger
oral
administr
parenter
administr
transgen
tobacco
mice
follow
presenc
igg
antibodi
serum
protein
g
rabi
viru
obtain
tobacco
concentr
solubl
protein
intraperiton
inject
tobacco
extract
mice
presenc
complet
freund
adjuv
induc
total
protect
viru
produc
antihepat
b
vaccin
lower
price
antigen
produc
transgen
potato
viral
protein
direct
endoplasm
reticulum
ad
cdna
signal
peptid
kdel
signal
retent
antigen
reticulum
observ
oral
immun
mice
presenc
cholera
toxin
induc
secret
highantibodi
titer
still
increas
boost
parenter
administr
potato
extract
retent
antigen
reticulum
may
play
role
bioencapsul
favor
immun
respons
synthesi
transgen
rice
epitop
known
induc
toler
toward
japanes
cedar
antigen
achiev
rice
extract
given
oral
mice
inhibit
ige
respons
antigen
recent
system
call
magnifect
shown
allow
rapid
product
within
two
week
gram
function
antibodi
plant
system
involv
transient
highlevel
coexpress
transgen
exampl
immunoglobulin
heavyand
lightchain
use
plant
virus
vector
deliv
agrobacterium
plant
bodi
although
encourag
result
predict
recombin
vaccin
prepar
transgen
plant
abl
reach
market
first
transgen
anim
gener
idea
use
anim
sourc
recombin
protein
propos
two
year
later
giant
mice
high
concentr
growth
hormon
obtain
shown
dna
microinject
use
gener
transgen
mice
could
extrapol
rabbit
sheep
pig
use
farm
transgen
anim
produc
recombin
protein
appear
realist
choic
milk
vehicl
made
one
year
later
two
protein
produc
milk
transgen
mice
proof
concept
follow
industri
develop
method
one
protein
human
antithrombin
iii
approv
european
agenc
emea
market
mean
time
larg
part
technic
obstacl
cross
problem
establish
transgen
line
ii
secret
foreign
protein
high
level
iii
purif
recombin
protein
iv
valid
protein
therapeut
case
case
basi
gener
transgen
farm
anim
may
achiev
accord
speci
dna
microinject
embryo
pronuclei
use
lentivir
vector
transposon
incub
sperm
dna
follow
vitro
fertil
use
icsi
intracytoplasm
sperm
inject
transfer
foreign
gene
pluripot
cell
embryon
stem
cell
primordi
germ
cell
follow
gener
chimer
anim
harbor
normal
transform
cell
transfer
foreign
gene
somat
cell
gener
clone
anim
use
nuclear
transfer
method
describ
recent
review
summar
fig
microinject
pronuclei
poorli
effici
rumin
speci
still
use
success
mice
rat
rabbit
pig
fish
increas
integr
frequenc
foreign
gene
introduc
integr
vector
transposon
lentivir
vector
latter
prove
highli
effici
rumin
pig
techniqu
adopt
experiment
even
vector
limit
capac
harbor
foreign
dna
integr
number
present
difficult
control
dna
transfer
via
sperm
develop
mainli
pig
mice
may
simplifi
transgenesi
case
util
cell
carrier
foreign
gene
use
mice
almost
twenti
year
case
pluripot
cell
capabl
particip
develop
chimer
transgen
anim
use
method
labori
use
gene
target
practic
essenti
inactiv
gene
gene
knockout
unknown
reason
possibl
obtain
use
pluripot
cell
embryo
es
cell
embryon
stem
cell
speci
mice
recent
studi
shown
chicken
quail
possibl
establish
pluripot
cell
line
eg
cell
pluripot
cell
present
fetal
gonad
pgc
primordi
germ
cell
made
possibl
gener
transgen
bird
candid
produc
recombin
protein
egg
white
clone
techniqu
use
gener
dolli
sheep
use
gener
transgen
rumin
pig
techniqu
allow
gene
addit
also
gene
target
homolog
recombin
make
possibl
gene
knockout
gene
target
also
way
integr
foreign
gene
genom
site
known
favour
express
gener
transgen
anim
remain
rel
labori
costli
hurdl
product
recombin
protein
milk
present
matur
system
produc
recombin
protein
transgen
organ
blood
milk
egg
white
semin
plasma
urin
silk
gland
insect
larva
hemolymph
theoret
system
tabl
silk
gland
promis
system
particular
case
preliminari
result
indic
activ
human
factor
vii
found
differ
tissu
transgen
fish
tilapia
known
system
may
improv
scale
mclean
unpublish
data
blood
store
high
level
recombin
protein
time
moreov
protein
blood
may
alter
health
anim
milk
avoid
essenti
problem
sever
mammalian
speci
rabbit
pig
sheep
goat
cow
current
use
produc
recombin
protein
milk
rabbit
offer
number
advantag
easi
gener
transgen
founder
offspr
high
fertil
rel
high
milk
product
insensit
prion
diseas
transmiss
sever
diseas
human
pig
costli
produc
higher
amount
milk
rabbit
rumin
potenti
appropri
speci
produc
larg
amount
protein
need
clone
lentivir
vector
integr
foreign
gene
reproduct
rel
slow
glycosyl
protein
well
rabbit
pig
sensit
prion
diseas
recent
egg
white
consid
promis
system
strongli
limit
great
difficulti
gener
transgen
bird
difficulti
appear
surmount
lentivir
vector
prove
effici
chicken
impress
pluripot
cell
line
establish
chicken
quail
cell
harbor
foreign
gene
reintroduc
earli
embryo
particip
develop
chimer
transgen
anim
previou
experi
group
show
chimer
transgen
chicken
gener
use
nonpluripot
cell
abl
secret
monoclon
antibodi
egg
white
antibodi
function
reduc
halflif
due
lack
sialic
acid
termin
end
carbohydr
chain
experi
valid
egg
white
sourc
foreign
protein
includ
recombin
vaccin
express
reliabl
manner
transgen
must
ideal
contain
promot
enhanc
insul
intron
transcript
termin
express
milk
achiev
success
promot
milkprotein
gene
express
egg
white
possibl
use
potent
promot
ovalbumin
gene
use
longgenom
dna
fragment
contain
promot
interest
gener
enhanc
greatli
express
foreign
cdna
prove
case
promot
one
milkprotein
gene
wap
gene
whey
acid
protein
suggest
element
longdna
fragment
use
futur
construct
compact
vector
express
transgen
reliabl
manner
construct
effici
express
vector
produc
therapeut
protein
standard
oper
two
exampl
may
illustr
point
recombin
vaccin
malaria
present
studi
one
protein
initi
obtain
mous
milk
produc
goat
milk
unexpectedli
antigen
produc
mous
milk
lost
vaccin
properti
glycosyl
second
exampl
product
protein
rotaviru
transgen
rabbit
milk
rotaviru
genom
form
sever
independ
rna
fragment
viru
replic
cytoplasm
protein
individu
secret
follow
modif
nucleotid
sequenc
perform
elimin
slice
site
sever
nglycosyl
site
addit
peptid
signal
adapt
codon
optim
express
two
cdna
mammari
gland
anim
modifi
cdna
introduc
vector
design
accord
criteria
defin
gene
construct
made
possibl
cosecret
milk
two
viral
protein
concentr
mgml
protein
abl
protect
mice
viru
complet
partial
accord
mode
administr
see
number
experi
shown
posttransl
modif
recombin
protein
secret
milk
may
incomplet
indic
cellular
machineri
mammari
gland
suffici
matur
complet
protein
secret
high
level
experi
carri
sever
year
ago
show
human
protein
c
found
mous
milk
partli
cleav
matur
process
complet
transgen
mice
express
furin
gene
code
cleavag
enzym
pioneer
work
indic
live
fermentor
mammari
gland
engin
perform
posttransl
modif
recombin
protein
identifi
produc
vaccin
protein
long
difficult
task
done
import
challeng
need
achiev
choos
suitabl
adjuv
enhanc
immun
respons
vaccin
antigen
togeth
choos
right
way
deliv
vaccin
recipi
critic
effici
recombin
protein
subunit
vaccin
poorli
immunogen
compar
whole
kill
liveattenu
pathogen
lack
import
featur
commonli
present
pathogen
like
lipopolysaccharid
lp
unmethyl
cpgcontainingdna
abl
activ
innat
immun
system
shape
adapt
immun
respons
toxic
reason
whole
kill
attenu
pathogen
use
mani
case
adjuv
need
increas
immunogen
subunit
vaccin
common
role
adjuv
enhanc
immun
respons
weak
antigen
also
implic
orient
respons
defin
type
cellular
humor
respons
field
adjuv
research
activ
sever
new
candid
develop
test
anim
human
addit
choic
formul
vaccin
deliveri
crucial
induc
appropri
protect
immun
respons
local
system
also
easi
handl
best
case
needlefre
noninvas
avoid
pain
requir
steril
materi
train
medic
worker
especi
import
vaccin
target
develop
countri
follow
section
summar
recent
advanc
field
despit
extens
evalu
sever
candid
past
year
aluminumbas
miner
salt
also
call
alum
adjuv
approv
us
food
drug
administr
fda
human
use
alum
well
toler
present
good
safeti
record
howev
rel
weak
adjuv
antibodi
induct
recombin
vaccin
induc
mainli
immun
respons
effici
activ
cellular
immun
thu
alum
adjuv
suitabl
antibodybas
protect
immun
requir
exampl
induct
neutral
antibodi
alum
lack
abil
induc
mucos
iga
imped
effici
sever
vaccin
strong
mucos
immun
need
prevent
pathogen
entri
replic
host
exampl
case
rotavirus
replic
intestin
caus
sever
gastroenter
intestin
iga
shown
protect
diseas
limit
alum
adjuv
increas
ige
product
allergen
neurotox
alum
also
effect
vaccin
formul
despit
extens
use
mani
year
alum
mechan
action
complet
understood
adsorpt
antigen
onto
alum
result
format
depot
site
inject
particul
structur
alumantigen
complex
may
facilit
uptak
antigen
present
cell
alum
could
activ
complement
macrophag
saponin
quil
deriv
bark
chilean
tree
quallaja
saponaria
purifi
extract
none
evalu
altern
alum
cellmedi
respons
activ
observ
toxic
local
reaction
hemolysi
associ
adjuv
render
use
human
limit
life
threaten
diseas
like
cancer
hiv
infect
immunostimulatori
complex
iscom
adjuv
compos
hydrophob
associ
cholesterol
phospholipid
quillaja
saponin
form
stabl
cagelik
structur
antigen
enclos
iscombas
vaccin
abl
induc
strong
antibodi
cellular
immun
respons
shown
number
differ
antigen
sever
anim
model
includ
nonhuman
primat
review
mous
iscombas
vaccin
shown
potent
induc
immun
respons
contrarili
aluminumbas
vaccin
nonhuman
primat
strong
longlast
respons
observ
follow
immun
core
protein
hepat
c
viru
hcv
complex
iscomatrix
preform
iscom
prepar
addit
humor
respons
mechan
action
iscom
fulli
understood
believ
particul
structur
uptak
antigenpres
cell
effici
saponin
compon
also
potent
adjuvant
see
shown
iscom
activ
innat
immun
system
mechan
human
number
clinic
studi
conduct
differ
vaccinebas
iscom
review
antibodi
andor
cellular
respons
induc
recipi
faster
antibodi
respons
higher
intens
observ
peopl
vaccin
influenza
iscombas
vaccin
iscombas
vaccin
administ
sever
recipi
show
safe
low
reactogen
common
advers
event
reaction
site
inject
myalgia
mild
intens
short
durat
iscom
appear
interest
candid
human
use
particular
iscomatrix
adjuv
well
character
appear
stabl
easi
handl
final
iscom
benefit
robust
reproduc
manufactur
procedur
scale
industri
product
cpg
dinucleotidescontain
oligodeoxynucleotid
cpg
odn
possess
adjuv
activ
shown
effici
differ
vaccin
formul
anim
human
cpg
odn
current
evalu
clinic
trial
human
field
infecti
diseas
cancer
treatment
asthmaallergi
cpg
odn
potent
orient
immun
system
toward
respons
therefor
primari
interest
vaccin
reaction
need
achiev
protect
immun
furthermor
cpg
odn
abl
stimul
mucos
immun
cpg
odn
even
show
greater
effici
administ
adjuv
like
alum
formul
like
lipid
emuls
nanoparticul
necessari
induc
protect
respons
antigen
weak
studi
mice
show
cpg
odn
boost
humor
cellmedi
immun
respons
broad
rang
protein
vaccin
exampl
inclus
cpg
odn
sar
coronaviru
subunit
vaccin
compos
fragment
spike
protein
alum
increas
titer
repres
respons
interferong
infg
secret
cell
observ
report
sever
subunit
vaccin
differ
pathogen
hepat
b
viru
herp
viru
rotaviru
exact
mechan
action
cpg
odn
precis
elucid
known
cpg
odn
act
mainli
activ
innat
immun
innat
compart
immun
system
evolv
recogn
gener
structur
commonli
found
broad
rang
pathogen
includ
structur
bacteri
mani
virus
dna
unlik
vertebr
genom
dna
contain
high
proport
unmethyl
cpg
dinucleotid
bacteri
pathogen
dna
recogn
directli
innat
immun
system
interact
tolllik
receptor
human
present
bcell
plasmacytoid
dendrit
cell
pdc
mice
also
express
monocyt
myeloid
dendrit
cell
effect
activ
induct
proinflammatori
tnfa
cellular
humor
immun
respons
review
cpg
odn
mimic
presenc
bacteri
dna
primarili
trigger
activ
innat
immun
system
cpg
odn
rapidli
intern
immun
cell
bound
activ
caus
cpg
odn
administr
enhanc
antigenspecif
humor
cellular
immun
respons
coadminist
antigen
contrarili
human
mice
express
bcell
pdc
also
monocyt
myeloid
dendrit
cell
observ
render
difficult
extrapol
encourag
result
obtain
mice
human
cell
may
play
import
role
vaccin
effici
howev
data
obtain
clinic
trial
human
show
efficaci
cpg
odn
adjuv
coadministr
cpg
odn
hepat
b
vaccin
engerixb
healthi
adult
volunt
either
alon
combin
alum
result
increas
igg
titer
compar
control
group
receiv
engerixb
alon
furthermor
hepat
bspecif
surfac
antigen
antibodi
appear
earlier
immun
carri
cpg
inclus
cpg
adjuv
also
increas
proport
antigenspecif
highavid
antibodi
acceler
antibodi
respons
combin
increas
magnitud
avid
also
observ
healthi
volunt
immun
anthrax
vaccin
adsorb
ava
cpg
odn
includ
far
treatment
cpg
odn
well
toler
advers
effect
observ
among
recipi
includ
pain
erythema
site
inject
mild
moder
flulik
symptom
last
imped
daili
life
activ
taken
togeth
result
underlin
potenti
cpg
odn
adjuv
anim
human
although
studi
need
import
point
remain
address
like
possibl
induc
autoimmun
diseas
recipi
cpg
odn
appear
promis
tool
interestingli
cpg
odn
could
benefit
largescal
good
manufactur
practic
industri
product
technolog
develop
past
year
antisen
drug
develop
approv
us
fda
two
bacteri
toxin
identifi
power
mucos
adjuv
cholera
toxin
ct
relat
heat
labil
enterotoxin
lt
produc
escherichia
coli
toxin
consist
catalyt
subunit
cta
lta
associ
pentamer
cellbind
b
subunit
cta
lta
subunit
possess
adpribosyl
transferas
enzymat
activ
result
perman
adenyl
cyclas
activ
target
cell
increas
camp
product
hypersecret
salt
water
bowel
ctb
ltb
part
allow
bind
cell
surfac
associ
gangliosid
result
intern
toxic
subunit
toxin
intern
polar
epitheli
cell
thought
coadminist
antigen
may
follow
rout
toxin
induc
strong
system
mucos
immun
respons
increas
respons
coadminist
antigen
vaccin
ct
lt
adjuv
produc
respons
show
excel
efficaci
induc
protect
immun
administ
via
nasal
rectal
rout
lesser
extent
via
oral
rout
howev
strong
toxic
molecul
preclud
use
human
ingest
mg
ct
human
would
result
induct
wateri
diarrhea
sever
less
toxic
deriv
retain
adjuvant
gener
sitedirect
mutagenesi
mutant
compris
lt
lt
lt
form
lt
lt
lt
bear
singl
amino
acid
substitut
catalyt
subunit
mutant
differ
residu
enzymat
activ
posit
correl
adjuvant
lt
contain
singl
amino
acid
substitut
proteas
sensit
portion
catalyt
subunit
mutant
reduc
enterotox
show
great
adjuvant
deliv
mucos
either
nasal
oral
rectal
rout
interestingli
intranas
deliveri
antigen
combin
ct
lt
deriv
induc
mucos
respons
even
distant
site
rotaviru
viruslik
particl
vlp
administ
intranas
strong
mucos
system
respons
induc
togeth
intestin
iga
product
encourag
result
obtain
use
strategi
consist
fuse
enzymat
activ
subunit
ct
bcelltarget
moieti
staphylococcu
aureu
protein
adjuv
call
far
less
toxic
intact
ct
contrarili
ct
produc
balanc
respons
also
shown
give
compar
protect
rotaviru
infect
compar
lt
cpg
furthermor
mice
receiv
nasal
administr
univers
influenza
vaccin
combin
complet
protect
lethal
infect
observ
togeth
reduct
morbid
context
immun
b
subunit
ct
ctb
lt
ltb
could
also
serv
mucos
adjuv
ctb
ltb
contain
adjuv
activ
administ
nasal
rout
mice
vaccin
influenza
viru
vaccin
ltb
show
higher
system
mucos
antibodi
respons
mice
receiv
vaccin
alon
interestingli
recent
studi
show
fusion
ctb
cpg
odn
cpgctb
result
enhanc
immunostimulatori
effect
cpg
odn
potent
stimulatori
effect
proinflammatori
cytokin
chemokin
respons
human
mous
splenocyt
worth
mention
addit
ct
lt
deriv
third
toxin
call
zonula
occluden
toxin
zot
show
adjuv
activ
identifi
zot
singl
polypeptid
chain
encod
filament
bacteriophag
ctxf
express
vibrio
cholera
zot
bind
receptor
intestin
epitheli
cell
increas
mucos
permeabl
act
structur
epitheli
tight
junction
phenomenon
believ
allow
penetr
antigen
tissu
interact
immun
cell
also
possibl
zot
act
codeliveri
system
antigen
may
also
immunomodulatori
properti
activ
antigenpres
cell
interestingli
effect
zot
exert
tight
junction
revers
caus
tissu
damag
sever
bacteri
toxin
adjuv
activ
also
identifi
studi
differ
group
review
mechan
action
still
need
clarifi
monophosphoryl
lipid
lp
major
constitu
gramneg
bacteria
lp
consid
endotoxin
induc
strong
proinflammatori
reaction
lp
strong
adjuv
properti
excess
product
proinflammatori
cytokin
link
repeat
administr
lp
lead
endotoxin
shock
character
inflamm
profound
hypotens
organ
failur
elev
toxic
lp
use
human
lpsmimet
compound
call
monophosphoryl
lipid
mpl
exhibit
adjuvant
low
toxic
gener
mpl
like
lp
act
interact
tolllik
receptor
antigen
present
cell
result
releas
proinflammatori
cytokin
like
tnfa
infg
ultim
enhanc
adapt
immun
respons
humor
cellular
preclin
studi
mpl
shown
gener
immun
respons
antigen
molecular
mechan
result
lower
toxic
mpl
versu
lp
clear
recent
okemoto
collegu
show
contrarili
lp
mpl
activ
macrophag
result
releas
pleiotrop
proinflammatori
cytokin
involv
endotoxin
shock
activ
also
involv
induct
endotoxin
shock
mpl
adjuv
synthet
analogu
compon
formul
often
use
clinic
trial
combin
alum
adjuv
design
compos
associ
alum
salt
mpl
shown
increas
antibodi
respons
papillomaviru
subunit
vaccin
human
formul
also
led
longlast
immun
vaccin
least
year
increas
memori
bcell
compar
alum
salt
formul
subject
receiv
mplformul
vaccin
herp
viru
hepat
b
viru
hbv
papillomaviru
extens
clinic
data
avail
adjuv
addit
mpl
present
approv
europ
use
combin
allergi
vaccin
present
differ
strategi
develop
optim
antigen
stabil
bioavail
host
reli
entrap
antigen
polymerbas
particl
case
microspher
lipidbas
membran
vesicl
case
liposom
microspher
compos
biodegrad
polym
mainli
polylactid
pla
poli
dllactidecoglycolid
plga
polym
degrad
vivo
form
nontox
lactic
glycol
acid
administ
microspher
allow
control
antigen
releas
may
form
depot
site
inject
allow
slow
releas
antigen
extend
period
thu
minim
number
dose
requir
immun
liposom
bilay
vesicl
compos
phospholipid
sterol
surround
aqueou
center
antigen
entrap
liposom
allow
prolong
releas
time
antigen
microspher
liposom
present
sever
advantag
like
increas
resist
degrad
antigen
gastrointestin
tract
control
antigen
releas
minim
number
dose
particl
uptak
immun
cell
abil
induc
cytotox
tlymphocyt
respons
adjuv
also
entrap
particl
enhanc
immun
respons
deliv
antigen
one
may
includ
type
formul
increas
vaccin
effici
choic
site
vaccin
deliveri
particularli
import
usual
vaccin
deliv
parenter
rout
either
subcutan
intramuscular
inject
immun
regimen
often
lead
induct
system
immun
respons
circul
antibodi
poor
mucos
immun
type
immun
suitabl
serum
neutral
antibodi
induct
need
prevent
pathogen
replic
reach
target
cell
host
exampl
case
hbv
vaccin
deliv
parenter
inject
neutral
antibodi
mediat
protect
howev
gener
consid
order
produc
protect
immun
best
vaccin
via
natur
rout
infect
pathogen
pathogen
infect
host
via
mucos
epithelium
repres
bodi
surfac
respiratori
tract
respiratori
synciti
viru
gastrointestin
enterotoxigen
e
coli
rotaviru
vagin
papillomaviru
hiv
rectal
mucosa
hiv
present
great
challeng
vaccin
stimul
strong
mucos
immun
prevent
pathogen
entri
host
easiest
way
administ
vaccin
oral
deliveri
howev
limit
exist
includ
degrad
antigen
harsh
gastrointestin
environ
acid
bile
salt
pancreat
secret
induct
oral
toler
antigen
one
major
featur
mucosaassoci
lymphoid
tissu
home
circul
activ
bcell
distant
effector
site
site
induct
featur
allow
exampl
product
intestin
vagin
iga
intranas
immun
intranas
immun
wide
use
mous
recogn
potent
induct
site
protect
immun
number
case
howev
immun
strategi
may
well
adapt
human
inde
nasal
epithelium
close
contact
olfactori
bulb
central
nervou
system
cn
close
vicin
structur
render
intranas
deliveri
bacteri
toxinbas
adjuv
danger
approach
mass
vaccin
sinc
toxin
coadminist
antigen
could
penetr
cn
see
also
niaid
juli
meet
summari
http
researchtopicsentericmeetingshtm
altern
immun
site
could
use
overcom
problem
exampl
vagin
intrarect
deliveri
antigen
latter
recent
shown
effici
vaccin
enter
pathogen
rotaviru
recent
transcutan
rout
shown
stimul
mucos
respons
mucos
immun
offer
number
import
advantag
includ
noninvas
needlefre
easi
administr
intranas
oral
intrarectalvagin
vaccin
also
conceiv
mucos
vaccin
could
selfdeliv
without
use
steril
equip
syring
train
medic
worker
may
real
advantag
vaccin
develop
countri
viruslik
particl
vlp
noninfecti
nonrepl
analogu
pathogen
virus
vlp
form
vitro
selfassembl
viral
capsid
protein
number
vlp
differ
virus
describ
date
like
papillomavirus
rotavirus
norwalk
virus
hepat
b
e
virus
parvovirus
name
use
vaccin
papillomaviru
hepat
b
viru
repetit
structur
arrang
capsid
protein
vlp
nativ
viru
particl
favor
activ
bcell
antibodi
product
vlp
also
effici
activ
cytotox
tcell
respons
absenc
infect
intracellular
replic
vlp
attract
tool
present
foreign
epitop
immun
system
chimer
vlp
describ
hepat
b
viru
hepat
e
viru
rotaviru
parvoviru
among
other
hbv
vlp
consist
fusion
hcv
epitop
hbv
core
protein
use
mice
immun
anti
hbv
antihcv
epitop
respons
observ
hbv
vlp
also
use
carri
larg
polypeptid
like
gfp
kratz
ectodomain
outer
surfac
protein
ospa
borrelia
burgdorferi
caus
agent
lyme
diseas
hbvospa
hybrid
vlp
immun
could
protect
mice
challeng
borrelia
burgdorferi
anoth
studi
inclus
bcell
epitop
tag
hepat
e
viru
hev
vlp
induc
specif
antibodi
respons
vlp
bcell
epitop
sedlik
et
al
show
porcin
parvoviru
capsid
protein
carri
tcell
epitop
lymphocyt
choriomening
viru
nucleoprotein
retain
capac
assembl
vlp
immun
mice
hybrid
vlp
result
strong
cytotox
tlymphocyt
respons
epitop
protect
mice
lethal
challeng
lymphocyt
choriomening
viru
import
mention
experi
vaccin
success
conduct
without
use
adjuv
underlin
immunostimulatori
effect
vlp
foreign
epitop
thu
combin
present
antigen
immunogen
repetit
structur
like
vlp
use
power
adjuv
result
increas
effici
immun
system
activ
otherwis
poorli
immunogen
solubl
antigen
approach
could
nice
strategi
elabor
combin
multival
vaccin
present
advantag
vaccin
carrier
vlp
introduc
epitop
recombin
vaccin
wellidentifi
theoret
advantag
convent
live
vaccin
yet
recombin
vaccin
remain
scarc
vaccin
hepat
b
one
vaccin
rhdv
rabbit
hemorrhag
diseas
viru
also
use
vaccin
rabbit
effici
vaccin
poultri
newcastl
diseas
prepar
transgen
plant
approv
put
market
far
four
plantderiv
recombin
vaccin
reach
clinic
develop
vaccin
malaria
produc
goat
milk
clinic
studi
wherea
vaccin
antirotaviru
produc
rabbit
milk
preclin
studi
identifi
relev
antigen
capabl
becom
effici
result
rel
longterm
studi
yet
antigen
character
could
prepar
valid
mode
administr
determin
valuabl
adjuv
requir
specif
studi
anim
model
model
alway
relev
mice
frequent
use
speci
purpos
anim
often
give
limit
inform
infect
rotaviru
follow
diarrhea
speci
easili
use
pig
monkey
requir
differ
system
product
recombin
vaccin
markedli
improv
last
decad
addit
progress
expect
state
art
field
hurdl
l
anim
cell
fermentor
avail
could
contribut
extens
product
recombin
vaccin
product
yeast
pichia
pastori
get
effici
reliabl
transgen
plant
still
face
import
problem
product
level
remain
often
low
glycosyl
problem
expect
solv
near
futur
uncontrol
dissemin
antigen
may
find
solut
implement
confin
area
market
protein
produc
plant
enzym
industri
applic
two
protein
clinic
studi
dog
lipas
patient
suffer
cystic
fibrosi
monoclon
antibodi
direct
streptococcu
mutan
prevent
tooth
decay
none
approv
yet
product
milk
matur
system
avail
produc
reliabl
recombin
vaccin
low
cost
spectacular
advanc
gener
transgen
chicken
express
monoclon
antibodi
egg
white
mg
per
egg
suggest
system
soon
contribut
boost
product
recombin
protein
transgen
anim
fact
atryn
human
antithrombin
iii
produc
goat
milk
approv
emea
contribut
compani
investor
confid
transgenesi
produc
biopharmaceut
technic
gap
therefor
account
slow
develop
recombin
vaccin
econom
reason
major
limit
field
import
note
vaccin
includ
eighth
posit
classif
biopharmaceut
vaccin
busi
hand
five
major
compani
focu
effort
influenza
childhood
diseas
demand
vaccin
includ
recombin
vaccin
remain
rel
modest
biopharmaceut
requir
rel
high
invest
research
amount
product
prepar
rel
low
vaccin
prevent
oper
impli
low
level
risk
price
vaccin
expect
low
especi
use
develop
countri
recent
rotaviru
vaccin
use
sever
countri
despit
risk
intussuscept
risk
due
vaccin
significantli
lower
risk
infect
recombin
vaccin
appear
better
tool
convent
vaccin
number
case
develop
might
becom
rapid
come
decad
increas
number
countri
govern
recommend
requir
systemat
vaccin
entri
children
school
recent
world
epidem
sar
influenza
inclin
govern
support
develop
new
vaccin
threat
bioterror
go
direct
develop
recombin
vaccin
thu
depend
polit
decis
technic
improv
still
need
improv
effici
recombin
vaccin
lower
product
cost
